Please assess the completion status of the following clinical trial:

Trial Title: Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected patients.~2. Age 18 or more.~3. Antiretroviral treatment containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) plus 1 Non-nucleoside reverse-transcriptase inhibitor (NNRTI) or 1 protease inhibitor (PI) or 1 integrase inhibitor (ININ)~4. Patients receiving stable antiretroviral treatment for at least 6 months.~5. Viral load under 50 copies/mL in the last 6 months~6. Patients with CCR5 tropism based in V3 genotyping in proviral DNA using the G2P with a false positive rate of 10% interpretation method.~7. A change of treatment is needed due to toxicity / tolerability problems with the 3rd drug (PI, NNRTI or ININ), according to investigator criteria.~8. An antiretroviral regimen containing a CCR5-antagonist is suitable for the patient (physician criteria).~9. Voluntary written informed consent.~Exclusion Criteria:~1. Pregnancy or breast-feeding.~2. Patient previously treated with maraviroc.~3. Patients with documented resistance to maraviroc or any other drug considered for the new ARV regimen.~4. Viral failure in the moment of inclusion.~5. Bad adherence history or anticipated (investigator criteria).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Change of 3rd drug to maraviroc (Type: EXPERIMENTAL): Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)

Based on this trial design, predict the completion outcome and termination type (if applicable).